This mouse study tested whether NMN could mimic parts of the heart-protective response associated with NAD+ metabolism during ischemia and reperfusion.
NMN increased cardiac NAD+ and reduced injury in the experimental mouse heart models under specific dosing and timing conditions.
The study is relevant to cardiac NAD biology, but it does not show that oral NMN supplementation prevents heart attacks or improves cardiovascular outcomes in humans.
Key findings
NMN increased myocardial NAD+ in the experimental models.
NMN reduced ischemia/reperfusion injury under the tested mouse protocols.
The work linked NAMPT/NAD+/SIRT1 biology with ischemic-preconditioning mechanisms.
The intervention and endpoints were preclinical.
What it cannot establish
Animal and ex vivo cardiac models only.
High experimental doses and acute timing are not equivalent to routine oral supplementation.
Ischemia/reperfusion models do not establish prevention or treatment effects in patients.
No human clinical outcomes were assessed.
HealthspanX claim boundary: This study does not establish that NMN prevents heart attacks, treats ischemic heart disease, or improves cardiovascular outcomes in humans.
